Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Post by MetzGERon Jul 14, 2020 1:58am
188 Views
Post# 31263865

The delay of the delay is delayed

The delay of the delay is delayed
VANCOUVER, BC – July 13, 2020 – Replicel Life Sciences Inc. (the "Company" or "Replicel")is pleased to provide this update on the status of the audit of its consolidated annual financial statements for the year ended December 31, 2019 (the “2019 Financial Statements”), the management discussion and analysis and the related officer certifications. As previously announced, the British Columbia Securities Commission issued a management cease trade order on June 17, 2020 because the Company was unable to timely file the 2019 Financial Statements, and the Company is filing this status update in accordance with National Policy 12-203, Management Cease Trade Orders, which requires bi-weekly updates by way of news releases.
The Company’s auditors are working on the audit, and the Company now expects to file the 2019 Financial Statements and related documents on or before July 30, 2020.


I am ashamed pretty bad 
Bullboard Posts